Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Metastatic Uveal Melanoma Overview 6 Therapeutics Development 7 Pipeline Products for Metastatic Uveal Melanoma - Overview 7 Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis 8 Metastatic Uveal Melanoma - Therapeutics under Development by Companies 9 Metastatic Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes 10 Metastatic Uveal Melanoma - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Metastatic Uveal Melanoma - Products under Development by Companies 13 Metastatic Uveal Melanoma - Products under Investigation by Universities/Institutes 14 Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development 15 Bellicum Pharmaceuticals Inc 15 Celldex Therapeutics Inc 16 Eli Lilly and Company 17 Novartis AG 18 Spectrum Pharmaceuticals Inc 19 Metastatic Uveal Melanoma - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 alpelisib - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 BPX-701 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 emibetuzumab - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 glembatumumab vedotin - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 KCN-1 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 LXS-196 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 merestinib - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 sotrastaurin acetate - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 vincristine sulfate - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Metastatic Uveal Melanoma - Dormant Projects 51 Metastatic Uveal Melanoma - Discontinued Products 52 Metastatic Uveal Melanoma - Product Development Milestones 53 Featured News & Press Releases 53 Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016 53 Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 53 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56

List of Tables Number of Products under Development for Metastatic Uveal Melanoma, H2 2016 7 Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Metastatic Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 15 Metastatic Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016 16 Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2016 17 Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2016 18 Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Metastatic Uveal Melanoma - Dormant Projects, H2 2016 51 Metastatic Uveal Melanoma - Discontinued Products, H2 2016 52 List of Figures Number of Products under Development for Metastatic Uveal Melanoma, H2 2016 7 Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Targets, H2 2016 21 Number of Products by Stage and Targets, H2 2016 21 Number of Products by Top 10 Mechanism of Actions, H2 2016 23 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23 Number of Products by Routes of Administration, H2 2016 25 Number of Products by Stage and Routes of Administration, H2 2016 25 Number of Products by Molecule Types, H2 2016 27 Number of Products by Stage and Molecule Types, H2 2016 27

Bellicum Pharmaceuticals Inc Celldex Therapeutics Inc Eli Lilly and Company Novartis AG Spectrum Pharmaceuticals Inc